Poliomyelitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major poliomyelitis markets are expected to exhibit a CAGR of 5.04% during 2024-2034.
The poliomyelitis market has been comprehensively analyzed in IMARC's new report titled "Poliomyelitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Poliomyelitis, commonly known as polio, refers to a highly infectious viral disease caused by the poliovirus. It primarily affects young children, but people of all ages can be impacted. Most individuals infected with the poliovirus experience no symptoms or only mild flu-like indications. However, in a small percentage of cases, the virus invades the nervous system, leading to more severe symptoms. This form of polio is characterized by muscle weakness or paralysis, often asymmetrically affecting the limbs. Various other indications may include loss of reflexes, muscle pain, fatigue, headache, fever, stiffness in the neck and back, etc. In rare cases, the virus can affect the muscles involved in breathing, potentially leading to respiratory distress or failure. Diagnosing poliomyelitis typically consists of a combination of clinical evaluation, laboratory testing, and epidemiological investigation. Initially, a healthcare professional will assess the patient's symptoms, medical history, and potential exposure to the poliovirus. A physical examination may reveal muscle weakness, decreased reflexes, or abnormal sensations. Several laboratory tests, such as viral culture or polymerase chain reaction (PCR), are used to detect the presence of the poliovirus in throat swabs, stool samples, or cerebrospinal fluid.
The increasing cases of poor sanitation, inadequate hygiene practices, and close personal contact, which can contribute to the transmission of the poliovirus, are primarily driving the poliomyelitis market. Moreover, the widespread adoption of non-opioid analgesics, such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), for reducing inflammation as well as relieving pain in patients without the risk of opioid-related side effects or dependency is further bolstering the market growth. Apart from this, the inflating application of various assistive devices, including braces, orthotics, canes, crutches, wheelchairs, etc., for enhancing mobility and independence for individuals suffering from polio is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of complementary therapies, such as acupuncture, acupressure, massage therapy, etc., since they can help to promote relaxation, improve blood circulation, and decrease muscle tension, is creating a positive outlook for the market. Additionally, the introduction of new vaccine formulations, including the inactivated polio vaccine (IPV) and the novel oral polio vaccine (nOPV), which aid in reducing the risk of vaccine-associated paralytic polio while maintaining high immunogenicity, is expected to drive the poliomyelitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the poliomyelitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for poliomyelitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the poliomyelitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the poliomyelitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the poliomyelitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current poliomyelitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the poliomyelitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the poliomyelitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the poliomyelitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of poliomyelitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of poliomyelitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of poliomyelitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with poliomyelitis across the seven major markets?
What is the size of the poliomyelitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of poliomyelitis?
What will be the growth rate of patients across the seven major markets?
Poliomyelitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for poliomyelitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the poliomyelitis market?
What are the key regulatory events related to the poliomyelitis market?
What is the structure of clinical trial landscape by status related to the poliomyelitis market?
What is the structure of clinical trial landscape by phase related to the poliomyelitis market?
What is the structure of clinical trial landscape by route of administration related to the poliomyelitis market?
The poliomyelitis market has been comprehensively analyzed in IMARC's new report titled "Poliomyelitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Poliomyelitis, commonly known as polio, refers to a highly infectious viral disease caused by the poliovirus. It primarily affects young children, but people of all ages can be impacted. Most individuals infected with the poliovirus experience no symptoms or only mild flu-like indications. However, in a small percentage of cases, the virus invades the nervous system, leading to more severe symptoms. This form of polio is characterized by muscle weakness or paralysis, often asymmetrically affecting the limbs. Various other indications may include loss of reflexes, muscle pain, fatigue, headache, fever, stiffness in the neck and back, etc. In rare cases, the virus can affect the muscles involved in breathing, potentially leading to respiratory distress or failure. Diagnosing poliomyelitis typically consists of a combination of clinical evaluation, laboratory testing, and epidemiological investigation. Initially, a healthcare professional will assess the patient's symptoms, medical history, and potential exposure to the poliovirus. A physical examination may reveal muscle weakness, decreased reflexes, or abnormal sensations. Several laboratory tests, such as viral culture or polymerase chain reaction (PCR), are used to detect the presence of the poliovirus in throat swabs, stool samples, or cerebrospinal fluid.
The increasing cases of poor sanitation, inadequate hygiene practices, and close personal contact, which can contribute to the transmission of the poliovirus, are primarily driving the poliomyelitis market. Moreover, the widespread adoption of non-opioid analgesics, such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), for reducing inflammation as well as relieving pain in patients without the risk of opioid-related side effects or dependency is further bolstering the market growth. Apart from this, the inflating application of various assistive devices, including braces, orthotics, canes, crutches, wheelchairs, etc., for enhancing mobility and independence for individuals suffering from polio is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of complementary therapies, such as acupuncture, acupressure, massage therapy, etc., since they can help to promote relaxation, improve blood circulation, and decrease muscle tension, is creating a positive outlook for the market. Additionally, the introduction of new vaccine formulations, including the inactivated polio vaccine (IPV) and the novel oral polio vaccine (nOPV), which aid in reducing the risk of vaccine-associated paralytic polio while maintaining high immunogenicity, is expected to drive the poliomyelitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the poliomyelitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for poliomyelitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the poliomyelitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the poliomyelitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the poliomyelitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current poliomyelitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the poliomyelitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the poliomyelitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the poliomyelitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of poliomyelitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of poliomyelitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of poliomyelitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with poliomyelitis across the seven major markets?
What is the size of the poliomyelitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of poliomyelitis?
What will be the growth rate of patients across the seven major markets?
Poliomyelitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for poliomyelitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the poliomyelitis market?
What are the key regulatory events related to the poliomyelitis market?
What is the structure of clinical trial landscape by status related to the poliomyelitis market?
What is the structure of clinical trial landscape by phase related to the poliomyelitis market?
What is the structure of clinical trial landscape by route of administration related to the poliomyelitis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POLIOMYELITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 POLIOMYELITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POLIOMYELITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 POLIOMYELITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POLIOMYELITIS - UNMET NEEDS
10 POLIOMYELITIS - KEY ENDPOINTS OF TREATMENT
11 POLIOMYELITIS - MARKETED PRODUCTS
11.1 List of Poliomyelitis Marketed Drugs Across the Top 7 Markets
11.1.1 Pediarix (DTaP-hepatitis B-poliovirus vaccine) - GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Vaxelis (Hib-DTaP-Hepatitis-B-Poliovirus-vaccine) - Merck
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Kinrix (DTaP-poliovirus vaccine paediatric) - GlaxoSmithKline
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Quadracel (DTaP poliovirus vaccine paediatric) - Sanofi
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Pentacel (Hib-DTaP-poliovirus vaccine) - Sanofi
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 POLIOMYELITIS - PIPELINE DRUGS
12.1 List of Poliomyelitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. POLIOMYELITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. POLIOMYELITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 POLIOMYELITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Poliomyelitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Poliomyelitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Poliomyelitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Poliomyelitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Poliomyelitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Poliomyelitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Poliomyelitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Poliomyelitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Poliomyelitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Poliomyelitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Poliomyelitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Poliomyelitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Poliomyelitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Poliomyelitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Poliomyelitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Poliomyelitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Poliomyelitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Poliomyelitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Poliomyelitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Poliomyelitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Poliomyelitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Poliomyelitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Poliomyelitis - Access and Reimbursement Overview
16 POLIOMYELITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 POLIOMYELITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 POLIOMYELITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 POLIOMYELITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 POLIOMYELITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 POLIOMYELITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 POLIOMYELITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 POLIOMYELITIS - UNMET NEEDS
10 POLIOMYELITIS - KEY ENDPOINTS OF TREATMENT
11 POLIOMYELITIS - MARKETED PRODUCTS
11.1 List of Poliomyelitis Marketed Drugs Across the Top 7 Markets
11.1.1 Pediarix (DTaP-hepatitis B-poliovirus vaccine) - GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Vaxelis (Hib-DTaP-Hepatitis-B-Poliovirus-vaccine) - Merck
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Kinrix (DTaP-poliovirus vaccine paediatric) - GlaxoSmithKline
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Quadracel (DTaP poliovirus vaccine paediatric) - Sanofi
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Pentacel (Hib-DTaP-poliovirus vaccine) - Sanofi
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 POLIOMYELITIS - PIPELINE DRUGS
12.1 List of Poliomyelitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. POLIOMYELITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. POLIOMYELITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 POLIOMYELITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Poliomyelitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Poliomyelitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Poliomyelitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Poliomyelitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Poliomyelitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Poliomyelitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Poliomyelitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Poliomyelitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Poliomyelitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Poliomyelitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Poliomyelitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Poliomyelitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Poliomyelitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Poliomyelitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Poliomyelitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Poliomyelitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Poliomyelitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Poliomyelitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Poliomyelitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Poliomyelitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Poliomyelitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Poliomyelitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Poliomyelitis - Access and Reimbursement Overview
16 POLIOMYELITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 POLIOMYELITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 POLIOMYELITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
